Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial [PDF]
, 2016 Dena Howard +9 more
openalex +1 more source
First-Line Treatment of Older Patients with CLL: A New Approach in the Chemo-Free Era [PDF]
, 2023 Antonio Urso +6 more
openalex +1 more source
Veterinary and Comparative Oncology, Volume 24, Issue 1, Page 41-50, March 2026.ABSTRACT Alkaline phosphatase (ALP) enzymatic activity has been proposed as a marker for distinguishing canine acute leukaemia (AL) subtypes (i.e., myeloid vs. lymphoid). However, ALP enzymatic activity has not been fully evaluated in CD34+ AL. Determine whether ALP enzymatic activity can differentiate CD34+ AL subtypes in dogs and distinguish CD34+ AL
Megan Aalto +7 more
wiley +1 more source
Supplementary Data from Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation
, 2023 YU Li-jian +15 more
openalex +1 more source
Assessing Adoption of Standard of Care and Comparing Clinical and Demographic Differences in First-Line (1L) Treatment (Tx) of Chronic Lymphocytic Leukemia (CLL) [PDF]
, 2023 Jing‐Zhou Hou +5 more
openalex +1 more source
Clinical, genetic, and familial features of POT1 tumor predisposition syndrome
Cancer, Volume 132, Issue 4, 15 February 2026.Abstract Background Protection of telomere 1 (POT1) tumor predisposition syndrome (POT1‐TPD) is a hereditary leukemia syndrome that is identified in ∼5% of patients with chronic lymphocytic leukemia (CLL) and is characterized by a predisposition to other cancers, including gliomas, melanomas, and angiosarcomas.
Courtney D. DiNardo +13 more
wiley +1 more source
The Increasing of Students’ English Speaking by Using Community Language Learning (CLL) through Students English Association of LP3I (SEAL) at Politeknik LP3I Medan [PDF]
, 2020 Ramadani Ramadani +3 more
openalex +1 more source